Abstract:Background: In the past two decades, a large-scale survey of hemoglobinopathies and thalassemia was carried out in mainland China, involving nearly one million people in 28 provinces. The incidences of hemoglobin (Hb) variants, α-thalassemia and β-thalassemia were 0.33%, 2.64% and 0.66%, respectively. The chemical structural analysis identified 67 Hb variants. Among them, 20 are new variants. The analysis of the α-globin gene organization in 111 HbH patients showed 76 cases (68.5%) were of the deletion type, 8 had Hb Constant Spring and the other cases were of non-deletion type. The results of the molecular characterization of more than 200 β-thalassemia alleles showed that the most common types of β-thalassemia mutations in China are CD 41/42 (−4 bp), IVS-II-nt.654 C→T, CD 17 A→T, CD 71/72 (+A) and −28 A→G. Methods: To explore the simple method for molecular diagnosis of β-thalassemia, multiplex allele-specific amplification (MAS-PCR) was used that could simultaneously detect the above five common types of β-thalassemia mutations. Results: Based on the molecular analysis of β-thalassemia intermedia, β-thalassemia homozygotes or compound heterozygotes combined with α-thalassemia, as well as the conjunctive abnormalities of β-thalassemia heterozygote with triplicated haplotype of α-globin genes, were the most common cause of thalassemia intermedia in China. We also used the RT-PCR quantitation method to show that the most common β-thalassemia allele, IVS-II-nt.654 C→T, still produced a small amount (about 15%) of normally spliced β-globin mRNA, therefore, causing β+-thalassemia. In clinical trials of hydroxyurea (HU) treatment for β-thalassemia patients, we found that HU may enhance the expression of the β-globin gene in some patients, leading to an alleviation of clinical symptoms. In the studies of the reversal of aberrant splicing of IVS-II-nt.654 C→T allele by the antisense approach, we constructed a mammalian expression vector that can produce an antisense RNA targeting against the aberrant splice sites of IVS-II-nt.654 C→T pre-mRNA. Conclusions: The results indicated that the antisense RNA produced from the vector could efficiently suppress the aberrant splicing pattern and restore the correct splicing pathway in vitro and in vivo, leading to the improvement of globin chain biosynthesis in thalassemia cells.

Diagnosis and Screening of Abnormal Hemoglobins

AB034. Hemoglobinopathies in China and SEA: Rapid Targeted Deep Sequencing for Molecular Screening and Clinical Genotyping in Subjects with Hemoglobinopathies

Inherited disorders of hemoglobin: A review of old and new diagnostic methods

Evaluation of role of HPLC (Merits & Pitfalls), in the diagnosis of various hemoglobinopathies & thalassemic syndromes

Establishing the Approach to the Diagnosis of Hemolytic Anemia in the Genetic Era: A Case Series

Update in Laboratory Diagnosis of Thalassemia

Recent progress in laboratory diagnosis of thalassemia and hemoglobinopathy: a study by the Korean Red Blood Cell Disorder Working Party of the Korean Society of Hematology

The Application of Clinical and Molecular Diagnostic Techniques to Identify a Rare Haemoglobin Variant

Advances in screening of thalassaemia

Rapid Targeted Next-Generation Sequencing Platform for Molecular Screening and Clinical Genotyping in Subjects with Hemoglobinopathies

Screening for hemoglobin disorders and investigating their hematological and demographic profile among patients attending a tertiary-care hospital in southern India-a descriptive study

Leveraging Multi‐Omics Approaches and Advanced Technologies to Unravel the Molecular Complexities, Modifiers, and Precision Medicine Strategies for Hemoglobin H Disease

Detection of 13 Novel Variants and Investigation of Mutation Distribution by Next Generation Sequencing in Hemoglobinopathies: A Single Center Experience

The phenotypic and molecular diversity of hemoglobinopathies in India: A review of 15 years at a referral center

A rare hemoglobinopathy duo: Hb Adana×Hb SEA in a 1-year-old patient - a case report and a brief literature review

The Studies of Hemoglobinopathies and Thalassemia in China--the Experiences in Shanghai Institute of Medical Genetics.

Thalassemia and Nanotheragnostics: Advanced Approaches for Diagnosis and Treatment

Genetic Modifiers of Hemoglobin Expression from a Clinical Perspective in Hemoglobinopathy Patients with Beta Thalassemia and Sickle Cell Disease

Recent Progress on Genetic Diagnosis and Therapy for Β-Thalassemia in China and Around the World

Screening and Diagnosis of Rare Thalassemia Variants

Molecular Diagnosis of Β-Thalassemia